Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales' disease

5Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: This study aimed to report the use of intravitreal bevacizumab as an adjunctive treatment in two cases of advanced Eales' disease with vitreous haemorrhage and tractional retinal detachment, prior to vitreoretinal surgery. Method: In two patients presenting with vitreous haemorrhage, retinal neovascularisation and localised tractional retinal detachment, 1.25 mg of intravitreal bevacizumab was injected prior to vitrectomy, membrane peeling and endolaser photocoagulation of retina. Result: Regression of the retinal neovascularisation with resolution of dye leakage on fluoroscein angiography was observed in both cases. Membrane peeling could be performed with minimal bleeding during vitreoretinal surgery in both cases. Conclusion: Bevacizumab may be a possible adjunctive treatment to vitreoretinal surgery for the management of Eales' disease with tractional retinal detachment. © 2011 The Author(s).

Cite

CITATION STYLE

APA

Thakar, M., Bamrolia, N. R., Raina, U. K., & Ghosh, B. (2012). Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales’ disease. Journal of Ophthalmic Inflammation and Infection, 2(2), 105–108. https://doi.org/10.1007/s12348-011-0049-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free